Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 5 Lymphoid 4 Plasma cell 3 Sarcoma 1 Other solid neoplasm 1 Other hematologic neoplasm 1 Gynecologic 1 Dermatologic 1 CNS 1

Conditions

Interventions

Nivolumab 168 Ipilimumab 152 pembrolizumab 143 Cyclophosphamide 126 Interleukin-2 70 aldesleukin 69 fludarabine phosphate 68 Radiotherapy 67 Biopsy 53 Temozolomide 48 Blood Specimen Collection 45 Peripheral Blood Stem Cell Transplantation 44 fludarabine 43 Radiosurgery 40 trametinib 38 Vemurafenib 36 dabrafenib 33 sargramostim 32 Bevacizumab 31 Aminolevulinic Acid 31 Magnetic Resonance Spectroscopy 30 Mycophenolic Acid 29 Specimen Handling 28 Whole-Body Irradiation 27 Photochemotherapy 26 Imiquimod 26 CTLA-4 Antigen 26 Busulfan 26 Tacrolimus 25 Surveys and Questionnaires 25

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × romiplostim × Dermatologic × Clear all

NCT04427306 2023-09-15

Neoadjuvant T-VEC in High Risk Early Melanoma

University of California, Davis

Phase 2 Suspended

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡